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The Role of Niacin in the 
Management of Dyslipidemia
Joseph M. Keenan
Abstract
Niacin or nicotinic acid has been used for the management of dyslipidemia 
for over 50 years, and it is the first medication that has been shown to reduce 
both coronary disease events and mortality. It is unique among the various lipid 
therapies in that it can not only reduce all of atherogenic lipid fractions (total 
cholesterol, low-density lipoprotein, very low-density lipoprotein, non-HDL 
lipoproteins, and triglycerides), but is also the most effective agent for raising 
high-density lipoprotein (specifically Apolipoprotein A-1). It is also the only 
lipid therapy that can lower lipoprotein (a). Niacin also has non-lipid benefits 
that improve vascular health and reduce atherogenesis. Niacin therapy was 
initially hampered by a high incidence of side effects, especially flushing, but 
this has largely been overcome by extended-release formulations and dosing 
and administering properly. Despite the failure of two recent clinical trials to 
show benefit of combining niacin with statins, there are many trials that support 
using niacin as monotherapy or in combination with other lipid agents including 
statins. Niacin is also the cheapest lipid agent available, and with the epidemic of 
cardiovascular disease in the world, it offers great value in the population-wide 
management of this health problem.
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1. Background: early niacin trials
Niacin or vitamin B3 comes in two forms, nicotinamide and nicotinic acid 
(NA), but only NA has lipid management benefits. The recommended daily 
allowance of vitamin B3 for nutritional benefit is only 20–30 mg/day, but the dose 
needed for lipid benefits is much higher and depends on whether one is using 
immediate-release (IRNA) 3000–6000 mg/day or extended-release (ERNA) 
1000–2000 mg/day formulations [1, 2]. The lipid benefits of NA were discovered 
serendipitously in the 1940–1950s when mega-doses of vitamins were being used 
in the management of mental health disorders. It was noted that high doses of 
NA lowered total cholesterol significantly. It was at that same time that elevated 
cholesterol was found to be associated with increased risk of cardiovascular 
disease (CVD) that led to the early trials of NA for management of dyslipidemia. 
Investigators in those early studies did not know what the mechanism of action of 
NA was but they were impressed that not only did NA lower total cholesterol by 
20+%, but also specifically lowered beta lipoprotein cholesterol (LDL-C), raised 
alpha lipoprotein cholesterol (HDL-C), and lowered triglycerides (TG) [3, 4].
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Lipid benefits
-Lowers total cholesterol
-Lowers LDL-C cholesterol (specifically low-density LDL-C)
-Lowers triglycerides
-Lowers Lp(a)
-Raises HDL-C (specifically apolipoprotein A-1)
Non-lipid benefits
-Inhibits vascular inflammation/reduces reactive oxygen species
-Reduces oxygenation of LDL-C
-Reduces intravascular adhesion molecules and monocyte chemo-attractant protein-1 (atherogenesis 
initiators)
-May reduce the size and functional recovery time of acute stroke
Ref. [7–9].
Table 1. 
Summary of niacin lipid and non-lipid cardiovascular benefits.
It became evident at that time that high cholesterol was not only associated 
with increased risk of CVD, but also diet and lifestyle interventions were usu-
ally not adequate to reduce cholesterol levels. This led to a large clinical trial, The 
Coronary Drug Project, that was a head to head trial of the cholesterol lowering 
agents available then (Thyroxine, Estrogen-two forms, Clofibrate and IRNA). The 
study was conducted from 1969 to 1975 and had five treatment arms and a large 
placebo arm totaling 8341 subjects [5]. The thyroxine and both estrogen treatment 
arms were terminated early due to lack of benefit and the clofibrate arm had some 
lipid improvements that failed to show reduction in coronary events. The IRNA 
arm not only demonstrated significant improvements in clinically important lipid 
fractions (total cholesterol, LDL-C, HDL-C, and TG) but, more importantly, it had 
a significant decrease in coronary events compared to placebo group. In addition, 
long-term (15 years) follow-up showed 11% decrease in mortality in the IRNA 
group compared to the placebo [6]. The only negative aspect of the Coronary Drug 
Project was the high incidence of flushing (>60%) in the IRNA treatment group. 
The immediate-release formulation of NA was used in that study, and, even though 
the majority of subjects were able to develop some level of tolerance, 8% had to 
drop out due to flushing.
2. NA mechanism of action
Nicotinic acid offers multiple clinical benefits to the lipid profile but the most 
unique and important is its ability to raise HDL-C. The 2017 Guidelines on the 
Management of Dyslipidemia list low HDL-C and a major risk factor for coronary 
disease because of important role of HDL-C in reverse cholesterol transport [7]. 
No agent is more potent at raising HDL-C than NA. NA not only NA raises HDL-C 
but also selectively prevents liver catabolism of apolipoprotein A-1, which is the key 
HDL lipoprotein needed for reverse cholesterol transport [8]. Thus NA increases 
both the capacity and the efficiency of HDL-C cholesterol transport. The liver is 
the site of synthesis of TG, very low-density lipoprotein (VLDL), lipoprotein (a) 
(Lp(a)), and LDL-C, and NA attaches to and antagonizes the hydroxycarboxylic 
acid-2 receptor of hepatocytes. This inhibits a hepatic microsomal enzyme (diacyl-
glycerol acyltransferase-2) that is necessary for the final step in the production of 
those lipids [8]. Not only does NA reduce the beta lipoproteins that make up LDL-C, 
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but also more specifically NA reduces the small dense LDL-C particles that are most 
atherogenic. Furthermore, NA is one of the best agents to lower TG and is the only 
medication that significantly lowers Lp(a), which is also a significant independent 
risk factor for coronary disease [7].
In addition, in vitro research using human aortic endothelial cells has demon-
strated impressive non-lipid benefits of NA in reducing risk of coronary disease. 
Researchers found that: (1) NA inhibits vascular inflammation by reducing reac-
tive oxygen species, (2) NA reduces LDL-C oxidation making it less atherogenic, 
and (3) NA reduces vascular adhesion molecules and monocyte chemo-attractant 
protein-1, which decreases the attachment of monocytes and macrophages to the 
vascular wall, a key element in early atherogenesis [8]. An animal study demon-
strated an additional non-lipid effect of NA, which is a neuroprotective benefit 
following stroke. The study involved inducing a stroke by middle cerebral artery 
occlusion in rats. Rats induced with NA within 2 hours of occlusion had a reduced 
volume of brain tissue damage and improved the functional recovery compared 
with controls [9] (Table 1).
3. Side effects of NA
Despite its many benefits, NA utilization can be hampered by a number of 
adverse side effects. The good news is virtually all NA side effects are reversible, and 
most can be minimized or eliminated by appropriate dosing and administration. 
The most common side effect is flushing and that is more common with IRNA and 
the initial doses of ERNA. Flushing is caused by release of prostaglandin D2 and 
prostaglandin E2 from Langerhans cells in the skin and macrophages [8]. In most 
persons, this flushing response can be minimized by proper dosing and administra-
tion (discussed later). William Parsons Jr., a co-investigator in the Coronary Drug 
Project and an early proponent of NA, was quite disappointed that many clinicians 
never learned “how to do” niacin resulting in higher dropout rates in NA therapy 
than that was warranted. This led him to writing a book, “Cholesterol Control 
Without a Diet! The Niacin Solution” for both lay and professional persons in an 
effort to educate all on proper NA administration [10].
Another side effect that is sometimes seen with ERNA therapy (but almost never 
with IRNA) is impaired liver function. This is due to methyl group depletion in the 
hepatocytes, secondary to the metabolic amidization in the liver of NA to nicotin-
amide [8]. This problem was shown to be preventable or reversible in most cases 
without loss of lipid benefit in studies using wax-matrix ERNA (WM-ERNA; Endur-
Acin by Endurance Products Inc.) by either dose reduction or methyl group supple-
mentation with methionine [11, 12]. Hepatic transaminase levels should be monitored 
during NA therapy. Modest transaminase level increases are acceptable, but NA dose 
reduction should be implemented if levels approach 2–3 times normal limits.
Increased blood glucose levels with NA therapy had raised concerns about its 
use in persons with diabetes or impaired glucose tolerance (metabolic syndrome). 
Blood glucose should be monitored in patients on NA treatment but that concern 
has been largely dismissed by the results from clinical trials. A controlled trial using 
WM-ERNA in non-diabetics showed only a 1% rise in baseline glucose levels at 
6 weeks that returned to baseline by 6 months [13]. The AIM-HIGH trial that used 
polygel ERNA (PG-ERNA; Niaspan, AbbVie Inc.) specifically recruited persons with 
low HDL-C and high TG (metabolic syndrome or MS) found a 5% rise initially from 
baseline glucose levels that returned to baseline over 2 years, and there was no dif-
ference in the development of diabetes in the two treatment groups [14]. A post-hoc 
analysis of the Coronary Drug Project (that used IRNA) found that the subgroup of 
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subjects with MS had comparable reduction in coronary events and long-term mor-
tality to the other subjects in the IRNA treatment group [15]. The consensus is that 
the benefits of treating lipid risk factors in persons with MS or diabetes outweighs 
any modest increase that NA treatment may cause to insulin resistance.
There are a number of less common side effects with NA treatment most of 
which are manageable without discontinuing therapy. Gastrointestinal upset can 
occur in some individuals and may be due to increased acid production on NA treat-
ment. This is usually managed by splitting the daily dose and taking it with meals. 
Acid blocking agents may also help. Hyperuricemia may also occur with NA treat-
ment and uric acid levels should be monitored routinely along with blood glucose 
levels and liver function tests. Nicotinuric acid is a by-product of liver metabolism 
of NA and can complete with renal excretion of uric acid causing levels to rise. The 
clinician must decide whether the continued use of NA would require additional 
management of uric acid levels is worth the lipid benefits. Increased homocysteine 
levels can occur with NA treatment and these should also be monitored routinely 
during NA therapy. Hyper-homocysteinemia is also a risk factor for cardiovascular 
disease that can be managed by folic acid supplementation. Some persons may 
experience a rash with flushing that usually clears with the development of toler-
ance, and in a rare instance, a darkened patch of skin may occur (acanthosis nigri-
cans). All of these side effects are completely resolvable/reversible by discontinuing 
NA if other management of the side effect is unsuccessful.
4. Selecting appropriate patients for NA therapy
As described above, the pleiotropic benefits of NA treatment make it an 
excellent choice for mixed dyslipidemias. One of the most prevalent forms of 
mixed dyslipidemia that is uniquely suited to NA treatment is MS (low HDL-C, 
high TG). A study of prevalence of MS in the United States showed 34% of all 
adults and 55% of persons over the age of 60 has MS [16]. An 8 year prospec-
tive study of cardiovascular risk (Framingham) in 3323 middle-aged adults in 
the United States found the risk of developing CVD over that 8 year period for 
persons with MS was 34% for men and 16% for women [17]. An epidemiology 
study of the prevalence of MS in European countries found it as high as 71.7% 
of adults in some countries and MS-associated CVD prevalence as high as 52% 
[18]. Thus, the prevalence and the high risk of CVD with MS make this a very 
large population of persons who would benefit from NA therapy, especially those 
persons with normal or modest elevations of LDL-C.
The problem of treating MS with NA as monotherapy is achieving the LDL-C 
goal for that person. Since cardiovascular risk assessment views MS as the equiva-
lent of having a prior coronary event the LDL-C goal is usually more aggressive 
(e.g.70 mg/dl) and that can be difficult to achieve on NA alone. A meta-analysis in 
2010 of NA studies using NA alone or in combination with other agents showed a 
26% reduction in coronary events. In addition, they showed a decrease in coronary 
atherosclerosis in 92% of persons treated with NA, as well as a reduction in carotid 
intimal thickness of 17 mm per year of NA treatment [2]. Most of these studies 
were conducted prior to the introduction of statins for lipid management. The 
compliment of the lipid benefits of NA and the effective LDL-C lowering benefit 
of statin drugs led to clinical trials using PG-ERNA with statins which did dem-
onstrate broad improvement of lipid profiles (decreased LDL-C, TG, Lp(a), and 
increased HDL-C) [19, 20]. Modeling of lipid therapy from these studies indicated 
that an ERNA with a statin would produce optimal lipid values for reducing 
coronary disease [21].
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The early success in lipid profile improvement of combination trials of 
PG-ERNA/statin led to the development of two very large clinical trials of combi-
nation PG-ERNA/statin therapy that were intended to demonstrate conclusively 
the benefit of combined treatment on the reduction of cardiovascular events and 
mortality (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/
High Triglycerides and Impact on Global Health Outcomes [AIM-HIGH] and Second 
Heart Protection Study—Treatment of HDL to Reduce the Incidence of Vascular 
Events [HPS-2 THRIVE]) [22, 23]. The much-anticipated results of those trials were 
very disappointing and not only failed to demonstrate reduction in vascular events 
but also appeared to show increased adverse events and side effects with that com-
bination. Critics of these two trials pointed out major design flaws in both studies 
that raise serious questions about the validity of any conclusions drawn from study 
results. The AIM-HIGH trial was terminated early because of what was thought to 
be an increase in cerebrovascular accidents in the PG-ERNA/statin treatment group, 
which in later analysis was found to be an artifact [22]. The main conclusion of the 
AIM-HIGH trial was that the combined PG-ERNA/statin treatment group did not 
show a decrease in cardiovascular events. This, in fact, was not true for the subgroup 
who were in the highest tertile of baseline TG and the lowest tertile of baseline 
HDL-C, both lipid fractions that benefitted from the NA addition to treatment [24]. 
Another AIM-HIGH post-hoc analysis of remnant lipoproteins and HDL-C2 showed 
that the PG-ERNA/statin treatment group did demonstrate improvements that could 
confer benefit in prevention of cardiovascular events, but perhaps this was not able 
to be demonstrated because of early termination [25]. Others also point out that the 
Coronary Drug Project took 6 years to demonstrate a reduction in coronary events 
with NA therapy, so the failure of AIM-HIGH and HPS-2 THRIVE to demonstrate 
the same may have been due to early termination of these studies [26]. Also, one of 
the lipid benefits of adding NA to a statin is the additional lowering of LDL-C which 
did occur in the AIM-HIGH trial. However, this benefit was muted since the control 
group had a second LDL-C lowering drug (ezetimibe) added to their treatment to 
match any LDL-C lowering by NA in the treatment group [22].
The HPS-2 THRIVE trial was actually PG-ERNA in combination with 
Laropiprant, a prostaglandin DP1 receptor inhibitor that reduces the NA flush-
ing side effect, and together this combination was added to statin therapy. The 
investigators had no idea when designing the study that the PG-ERNA/Laropiprant 
combination would cause such an increase in myopathies especially in Chinese 
subjects. Of the 25,673 study subjects over 11,000 were Chinese, and their annual 
incidence of myopathy was 800% greater than that European subjects on the same 
treatment [27]. Critics of the HPS-2 THRIVE trial felt the addition of Laropiprant 
to the NA treatment group confounded the outcomes and thus they do not accept 
it as a legitimate study of the combination of NA and statin therapy [26]. The main 
conclusion of the HPS-2 THRIVE study was similar to the AIM-HIGH study; that is, 
the addition of NA to statin therapy did not improve cardiovascular outcomes, and, 
in fact, resulted in an increase in serious adverse effects [23]. Despite the design 
flaws in these large trials, the consensus is that adding NA to statin therapy in per-
sons who are already at their LDL-C goal does not improve clinical outcomes. These 
two large studies raised serious questions about what is the appropriate combina-
tion therapy with statins in persons who have not reached their LDL-C goal. While 
this controversy still lingers, many feel the effectiveness of NA in reducing LDL-C 
(especially small dense LDL-C particles) as well as the other lipid benefits as shown 
in earlier studies continues to make NA an appropriate combination with statins to 
achieve lipid goals and desired clinical endpoints [26].
Recent changes in recommendations of national cholesterol treatment guidelines 
in the United States have increased the number who are considered eligible to start 
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statin therapy (absolute risk of cardiac event >7.5% over 10 years) to over 50 million 
persons [28]. The rate of statin intolerance (stopping therapy) in general population 
cholesterol intervention is 18–20% or about 10 million persons (statin intolerant) in 
the United States who are candidates for other lipid therapy interventions [29]. This 
represents another large target group that is appropriate for NA therapy since none 
of the other agents available have abroad range of lipid and non-lipid benefits for 
prevention of CVD [8, 26]. Some have suggested that proprotein-convertase subtili-
sin/kexin type 9 (PCSK-9) inhibitors be used when statin intolerance is encountered. 
At a cost of $15,000/year for PCSK-9 inhibitors and an estimated incremental cost of 
$330,000 per quality-adjusted life-years (QALYs), this option is very limited [30].
Perhaps the largest group of persons who would be logical candidates for NA 
lipid therapy globally are those whose risk scores indicate need to initiate lipid 
treatment but either they, individually, or their health system cannot afford statin 
treatment. Cardiovascular disease has grown at epidemic rates in developing coun-
tries and those countries account for over 80% of all cardiovascular deaths annually 
[31]. Using microsimulation modeling, analysts recently demonstrated that initiat-
ing statin therapy at the recommended 7.5% risk threshold would be an incremental 
cost-effectiveness ratio of $37,000 per QALYs gained [32]. This may be considered 
cost-effective in a developed country, but in a developing country this is prohibi-
tive. Not only does NA have the broadest profile of lipid and non-lipid benefits for 
coronary disease/mortality reduction, it is also the cheapest available lipid lowering 
agent. Thus, it makes sense as a public health strategy for developing countries to 
initiate population level of lipid therapy intervention with NA monotherapy adding 
other agents as needed, and reserve initiation with statin therapy to the subset of 
persons with high/very high risk status.
Persons with isolated dyslipidemic fractions such as low HDL-C, or high TG are 
also reasonable candidates for NA therapy and NA is the only agent at present that 
can significantly lower Lp(a). A meta-analysis of clinical trials specifically target-
ing hypertriglyceridemia (two trials were NA monotherapy, one NA with fibrates) 
showed significant reduction in coronary events especially if high TG was associ-
ated with low HDL-C [33]. A meta-analysis of clinical trials of NA to lower Lp(a) 
showed significant reductions of 22–24%, and a case report of NA with a statin 
showed a dramatic 88% reduction [34, 35].
5. Choosing an NA formulation
The early clinical trials of NA used immediate-release formulations with good 
lipid results but many of those trials had unacceptably high drop-out rates due 
to flushing [36]. In an effort to reduce the flushing side effects, sustained-release 
NA formulations were developed. These did reduce flushing but continuous/
sustained exposure of the liver to NA resulted in a high incidence of impaired liver 
function [36]. Researchers found that an intermediate (between immediate and 
sustained) or ERNA provided the best reduction in flushing side effects and also 
reduced the liver issues encountered with the more sustained-release formulations 
[36]. Another formulation that was made popular by its “no flush” claim is inositol 
hexanicotinate (six molecules of niacin attached to inositol). There are many NA 
products available on-line and over-the-counter that claim to be extended-release 
preparations but most of them have not been studied for safety, efficacy, and side 
effects in controlled clinical trials. Poon conducted an in vitro dissolution study 
of 19 non-prescription NA products comparing them to 1 prescription PG-ERNA 
product (Niaspan) [37]. He found wide variation in dissolution rates suggesting the 
in vivo NA release from these products would difficult to predict.
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In selecting an NA product for clinical use, it is best to stay with products that 
have demonstrated safety and efficacy in clinical trials. The PG-ERNA, Niaspan, 
is the only NA formulation that has been approved by the US Food and Drug 
Administration for lipid therapy and is the standard by which other NA products 
are measured. It is by far the most extensively tested NA formulation having been 
used in both monotherapy and combined therapy with other agents including 
the AIM-HIGH and HPS-2 THRIVE studies. It has consistently demonstrated the 
desired lipid benefits and has typically had a total drop-out rate of 18–19% (9–10% 
due to flushing intolerance and 8–9% due to other adverse effects) [38]. Another 
polygel extended-release NA product, Slo-Niacin (Upsher-Smith Inc.) has also been 
extensively tested in clinical trials and was used in a large Veteran’s Administration 
NA interchange study. Veterans who were on Niaspan (5321 subjects) were switched 
to Slo-Niacin and followed for 2 years. The results showed comparable safety/side 
effects and lipid benefits and Slo-Niacin had even greater lowering of TG [39]. A 
third NA product that uses a wax-matrix for its extended-release formulation is 
Endur-Acin (Endurance Products Inc). Endur-Acin has demonstrated comparable 
if not better lipid results compared the PG-ERNAs and it has exceptional safety and 
side effect rates with an average total drop-out rate of only 3–8% for 4 clinical trials 
totaling more than 400 subjects [11, 13, 40, 41]. Since age is one of the strongest 
non-lipid risk factors for CVD, it is worth noting that a post-hoc analysis of one of 
the Endur-Acin trials showed that older persons enjoyed even better lipid results 
than younger persons with no increase in side effects or drop-out rates [42]. The 
only clinical trial testing inositol NA as monotherapy showed its claim of “no flush” 
is a scam. In a head to head comparison trial with wax-matrix NA (Endur-Acin) 
that included pharmacokinetics of both agents, wax-matrix NA demonstrated an 
optimal extended-release and absorption curve over 8 hours and inositol NA had a 
flat line absorption curve demonstrating no bioavailability at all [41] (See Figure 1).
6. NA dosing and administration: “How to do” niacin
Guidelines recommend determining the patients risk score for likelihood of 
a coronary event in the next 10 years and discussing treatment options and goals 
before initiating treatment. Initiation of NA therapy also should be preceded by 
Figure 1. 
Mean blood levels (ng/ml) over 8 hours of NA after single dose of 500 mg of wax-matrix nicotinic acid 
(WMER) and 500 mg dose of inositol hexanicotinate (IHN).
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baseline check of lipids, blood glucose, hemoglobin A1C, uric acid, homocysteine, 
and liver transaminases to be sure the patient is an appropriate candidate. If you 
are primarily targeting low HDL-C with NA therapy, the most effective formula-
tion is IRNA. Even though that form of NA has the highest rate of flushing it can 
be minimized in most persons by proper dosing and administration: (1) initiating 
therapy at a low dose (250–500 mg) and gradually increasing over 1–2 weeks to 
allow tolerance to develop, (2) giving aspirin with the dose of NA to block the 
prostaglandin response, and (3) giving the NA dose with meals to slow the rate 
of absorption. The Coronary Drug Project using IRNA had only an 8% drop-out 
rate due to flushing. Typically, IRNA dosing is advanced to at least 3000 mg/day 
for optimal HDL-C response but can be increased to as high as 6000 mg/day in 
divided doses with meals to reach goals as tolerated. Lipids and blood chemistries 
should be rechecked at 6 weeks and monitored at 6 week intervals until targeted 
dose has been reached. If chemistries remain within normal limits (liver transami-
nases acceptable up to three times, the upper limit of normal) then monitoring 
interval can be extended to 3 months once targeted dose has been reached. For 
most persons whose liver function tests approach/exceed three times the upper 
limit of normal, simply reduce dosage by half and recheck tests in 2 weeks. They 
are most likely sensitive to the amidization metabolism of NA in the liver and are 
becoming depleted of methyl groups. They will usually continue to have excel-
lent lipid results at the lower dose and will also benefit from a diet rich in “methyl 
donor” foods (kale, berries, fish, nuts, etc.) or taking a methionine supplement. 
In the Endur-Acin versus inositol clinical trial six persons on Endur-Acin had dose 
reduction due to liver enzyme elevations, yet all had a good lipid response and five 
were able to reach their LDL-C goal [41]. If additional lipid lowering agents are 
needed, follow up can be adjusted to take into consideration monitoring that added 
agent or any possible interactions of agents.
For essentially all other NA lipid therapies (other than isolated low HDL-C), ERNA 
is better tolerated and more effective for the other lipid fractions. Initiating dosing for 
ERNA therapy is essentially the same as IRNA as listed above. Most of the PG-ERNA 
studies have used one time/day dosing at bedtime with a small snack for two reasons: 
(1) convenience (and it can be given at the time a statin is supposed to be given) and 
(2) to match the time of peak hepatic lipid synthesis. The PG-ERNAs (Niaspan and 
Slo-Niacin) also have a somewhat higher rate of flushing than the WM-ERNA (Endur-
Acin) so giving it in a near fasting state may also reduce the chance of early breakdown 
of the polygel capsule that might happen with the increased peristaltic activity of a 
meal. Critics of the bedtime NA dosing used in the AIM-HIGH and HPS-2 THRIVE 
studies, however, point out that dosing NA in a fasting or near fasting state causes a 
drop in non-esterified fatty acids. This in turn can inadvertently cause a transient drop 
in blood glucose triggering release of epinephrine and hepatic gluconeogenesis which 
might have caused some of the negative results found in those studies [26]. Also, 
persons taking any ERNA should be cautioned to avoid consuming a hot beverage with 
dosing since that can accelerate NA release and risk flushing.
In targeting appropriate patients for NA lipid therapy, it is helpful to know what 
lipid changes to expect for typical dosing of NA. Increases in HDL-C are typically 
in the +12 to +22% range with an IRNA dose of 3000 mg or an ERNA (Niaspan, Slo-
Niacin, Endur-Acin) dose of 1500–2000 mg with IRNA and Niaspan being toward 
the better response end. Decreases in LDL-C for those agents are typically in the −12 
to −26% with Endur-Acin toward the better response end. Decreases in TG are typi-
cally −10 to −15% and Lp(a) about −18 to −22% [11, 43–45]. Knowing the patients 
baseline lipid/chemistry levels and their 10 year coronary risk score can help in 
choosing an NA agent and dosing strategy. A person with isolated low HDL-C 
would be a good candidate for IRNA or possibly Niaspan if they do not tolerate the 
9The Role of Niacin in the Management of Dyslipidemia
DOI: http://dx.doi.org/10.5772/intechopen.81725
flushing with IRNA. A person with MS, since they are considered higher risk for a 
coronary event (lower LDL-C goals), might do well to start on Endur-Acin and get 
the extra LDL-C benefit. In a clinical trial using Endur-Acin in persons with mild 
to moderate dyslipidemia 78% of persons with 0–1 cardiac risk factor and 44% of 
persons with 2 or more risk factors were able to get to their LDL-C goal along with 
the additional NA benefits in other lipid fractions [41]. A person whose baseline 
chemistries suggest glucose intolerance might best be placed on mealtime dosing to 
avoid reactive hypoglycemia and epinephrine release, and, of course, anyone with 
pre-existing liver function issues would best be started on IRNA. Management of 
side effects and adverse events from NA therapy are covered above (side effects of 
NA). Despite the bad press from the AIM-HIGH and HPS-2 THRIVE studies, NA 
has been used successfully with virtually every class of lipid lowering agent espe-
cially statins. With the possible exception of adding NA therapy to a person who is 
already at their LDL-C goal on statins, providers should feel comfortable adding 
other agents to NA or NA to other agents to achieve lipid goals [46, 47].
Last but not least in considering NA for lipid therapy is the cost. There are 
many very inexpensive NAs available in pharmacies, health supplement stores, 
and on-line, all claiming to lower cholesterol. But the patient should be advised to 
stay with those products that have been proven safe and effective in clinical trials, 
and specifically to avoid the NAs that claim “no flush” (inositol hexanicotinate) 
that have been proven “no benefit”. Endur-Acin (WM-ERNA) and Slo-Niacin 
(PG-ERNA) are available on-line for only $8–9.00 USD/month for treatment (www.
endur.com; www.slo-niacin.com). Niaspan is available only by prescription and is 
more expensive as are generic statins which are about 5–6 times more expensive. 
The cost may not be a big issue for persons with full drug coverage health insurance. 
But for others, even those with a co-pay, taking a medication that you will need for 
the rest of your life can be a substantial expense.
7. Conclusion
Nicotinic acid is the first dyslipidemia medication to reduce both CVD events 
and mortality. No other lipid medication has the breadth of lipid and non-lipid 
benefits for managing CVD risk. Specifically, NA is the best agent for raising 
HDL-C, one of the best agents for lowering TG and the only medication that 
can significantly lower Lp(a). This is in addition to ability of NA to significantly 
lower LDL-C, and non-HDL-C. Unique non-lipid benefits include reduction of 
LDL-C oxidation and other oxidative species as well as prevention of inflam-
matory adhesion molecules in the vascular intima all of which are associated 
with atherogenesis. The initial clinical experience with IRNA was hampered 
by fairly high rates of flushing intolerance, but this has been largely overcome 
by the development of ERNA and attention to proper dosing and administra-
tion. Initial clinical trials of NA as monotherapy and in combination with other 
agents (statins, fibrates, and bile acid sequestrants) all showed significant lipid 
benefits. Two very large clinical trials (AIM-HIGH, and HPS-2 THRIVE) that 
were intended to confirm the benefits of NA/statin combined therapy had very 
disappointing results. Unfortunately, despite significant design flaws in these two 
studies, their results have led to widespread discontinuance of NA, both in com-
bination with statins and even NA monotherapy. The real conclusion that seems 
supported by the two large clinical trials is that adding NA to statin treatment 
when a person is already at their LCL-C goal probably does not add benefit. But 
to disregard all of the prior positive NA studies and the fact that these large trials 
had serious design flaws is unfair judgment of NA. In fact, a 2013 meta-analysis 
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of prior NA trials of both monotherapy and NA combined with other agents 
(included the Aim-High trial) showed that NA reduced risk of any CVD event by 
34% and specifically major coronary event by 25% [48]. A similar meta-analysis 
of statin trials showed a 22 and 27% risk reduction for the same endpoints, 
respectively [49]. The obvious preference for statins when initialing lipid therapy 
is based on its effectiveness in lowering LDL-C, the prime lipid target in CVD 
risk reduction. But the NA trial with Endur-Acin showed that in a population 
with mild to moderate dyslipidemia, 50% or more of persons can reach their 
LDL-C goal with NA monotherapy and enjoy the additional lipid and non-lipid 
CVD benefits of NA therapy. Also, a recent study designed to evaluate the effects 
on atherogenic factors (lipid and non-lipid) when ERNA is added to statin 
therapy in MS patients showed an impressive array of positive benefits [50]. So, 
providers should continue to value its use in the many dyslipidemia patients who 
are appropriate for NA therapy and learn “how to do” NA for optimal results.
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